HAE: Rounding Bottom detected on 2 Sep 2026

HAE is forming a rounding bottom pattern with a structure score of 15.0 and composite quality score of 72 (overall). The stock currently trades at $101.95, positioned 6.95% below its 52-week high of $109.57 and well above support at $83.49 (key resistance recently). Volume is soft at 633,647 shares (0.77x average), suggesting weak confirmation on the breakout attempt. The RSI of 63.83 indicates moderate momentum without overbought conditions. The pattern suggests a potential measured move target of $106.37, implying modest upside of 4.3% from current levels. Win probability is 68.51%, reflecting decent structural quality despite soft volume metrics.

HAE delivered Q1 fiscal 2026 revenue of $339.4M, well ahead of the Wall Street estimate of $327.9M, with adjusted EPS of $1.14 versus $0.87 expected. On August 21, 2026, Baird raised its price target to $119 from $96, signaling renewed analyst conviction. The company acquired the remaining majority stake in Vivasure Medical Limited for approximately €190 million on January 9, 2026, bolstering its vascular closure portfolio. The company generated free cash flow of about $44.4M in the latest quarter with interest coverage over 20x. The strong earnings beat and upgraded guidance triggered a rapid move from $78.78 on July 24 to $104.65 by mid-August, establishing the base conditions for this rounding bottom. Health care sector momentum remains bullish (regime score 0.51), supporting the pattern formation.

A successful breakout above resistance near $106.37 would confirm the rounding bottom completion. The pattern indicates a measured conservative target of $106.37, with volume confirmation needed as current relative volume of 0.77 lags the 20-day average of 822,519 shares. Historical win probability of 68.51% suggests two-in-three chance of directional success. Invalidation occurs decisively below key support at $83.49, representing a maximum risk zone of approximately 18% downside from current price. The breakout would need to reclaim and hold above the recent intraday highs near $106-$107 with volume acceleration to establish follow-through.

Earnings are scheduled for November 5, 2026, introducing event risk. Recent weakness (down 5.88% in the past week despite the 3-month rally of 53.61%) signals potential exhaustion or profit-taking after the August-September surge. MACD histogram is negative at -0.3629, suggesting momentum may be turning despite RSI near midpoint. The market regime is bearish (score -0.23), conflicting with this health care sector's bullish posture—macro headwinds could override sector strength. Volume deterioration to 77% of average indicates weak conviction from buyers, risking a failed breakout. Beta of 0.48 offers some downside protection, but the high P/E multiple cited near 40-50x leaves little room for disappointment on upcoming earnings.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.